Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis” [J Hepatol 71 (2019) 543–552]

Published:October 25, 2019DOI:

      Linked Article

      • Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
        Journal of HepatologyVol. 71Issue 3
        • Preview
          Worldwide, liver cancer is predicted to be the fourth most common cause of cancer-related mortality, accounting for an estimated 782,000 deaths in 2018, with most liver cancers HCC.1 However, there are global differences in HCC incidence and trends, with Eastern and Southeast Asia having among the highest incidence of liver cancer.1 This difference in HCC incidence between Asian and non-Asian regions is related to the high incidence of chronic viral hepatitis in Asia.2,3 Most Asian countries have high rates of HBV infection,2 with the exception of Japan, which has the highest rate of HCV infection of all industrialised countries.
        • Full-Text
        • PDF
        Open Access
      It has come to our attention that there is an error in Table 4 of our manuscript. In the row ‘Chemotherapy’, the values for the Asian cohort should read 37 (44), rather than 37 (43). Please see corrected Table below:
      Table 4Subsequent therapy after nivolumab progression.
      TherapyITT population (n = 182)Asian cohort (n = 85)
      Any subsequent therapy, n (%)94 (52)53 (62)
      Radiotherapy40 (22)22 (26)
      Surgery17 (9)9 (11)
      Systemic therapy62 (34)36 (42)
       Chemotherapy45 (25)37 (44)
       Targeted therapy37 (20)20 (24)
       Immune checkpoint inhibitor9 (5)5 (6)
       Other immunotherapy5 (3)5 (6)
       Experimental therapy18 (10)9 (11)
       Other10 (5)9 (11)
      Local therapy34 (19)24 (28)
       TACE24 (13)19 (22)
       HAI chemotherapy5 (3)5 (6)
       Other10 (5)4 (5)
       Radiofrequency ablation3 (2)3 (4)
      HAI, hepatic artery infusion; ITT, intent-to-treat; TACE, transcatheter arterial chemoembolisation.